Audentes therapeutics, inc. (BOLD)
CashFlow / TTM
Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Cash flows from operating activities:
Net loss

-175,488

-166,038

-152,641

-128,821

-117,604

-106,322

-97,694

-90,238

-85,539

-75,899

-67,319

-59,668

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

7,395

6,895

6,146

5,595

4,888

4,297

3,815

3,398

3,108

2,842

2,284

1,630

0

0

0

Amortization of right-of-use assets

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

21,723

20,644

18,610

16,495

14,942

11,839

9,210

6,880

4,751

3,820

2,732

2,004

0

0

0

Accretion of discount on marketable securities

3,883

3,555

2,830

1,861

1,032

634

446

350

325

176

107

-51

0

0

0

Accretion of asset retirement obligation

-

-

-

-

-

-

-

-

-

-

-

106

0

0

0

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability

144

103

-36

-2,298

-2,224

-2,244

-2,111

263

-34

84

102

102

0

0

0

Other

-493

-537

-527

-555

-148

-207

-318

-337

-277

-168

-93

-71

0

0

0

Changes in operating assets and liabilities:
Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Prepaid expenses and other current assets

347

816

611

2,150

911

1,459

-91

675

-1,200

-5,100

-1,996

-1,085

0

0

0

Other assets

-

-

-

-

-

-

-

2,012

2,041

2,061

1,373

-27

0

0

0

Accounts payable

4,875

3,062

5,337

4,081

-1,249

-163

2,512

686

1,611

1,182

422

-671

0

0

0

Accrued liabilities

-1,070

966

1,596

2,017

4,603

1,078

-773

-1,579

2,050

2,994

2,236

4,815

0

0

0

Deferred rent

-287

68

-1,451

-1,619

-1,082

-1,377

-952

-937

-1,215

-1,181

-626

-1,522

0

0

0

Operating lease liabilities

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-147,400

-143,078

-125,606

-107,978

-102,793

-94,218

-86,950

-84,565

-73,210

-56,041

-58,284

-48,926

0

0

0

Purchases of property and equipment

13,552

11,880

11,976

11,609

10,594

10,704

7,720

7,551

7,325

10,023

15,258

16,651

0

0

0

Proceeds from maturities of marketable securities

462,057

385,659

320,613

208,586

171,180

157,698

129,593

126,828

98,355

85,291

73,405

58,624

0

0

0

Purchases of marketable securities

568,176

561,539

464,219

382,025

245,291

166,635

161,577

152,713

168,598

132,881

115,811

104,037

0

0

0

Net cash used in investing activities

-119,671

-187,760

-155,582

-185,048

-84,705

-19,641

-39,704

-33,436

-77,567

-57,612

-57,648

-62,048

0

0

0

Proceeds from exercise of stock options and ESPP purchases

10,200

7,306

6,242

4,049

3,384

2,413

1,501

828

658

425

215

157

0

0

0

Proceeds from issuance of common stock, net of issuance costs

217,062

208,734

177,291

394,413

234,426

270,871

336,847

119,725

0

0

0

-

-

-

-

Net cash provided by financing activities

226,466

215,482

183,538

398,462

237,810

273,284

338,348

120,553

117,681

156,211

75,423

75,365

0

0

0

Net (decrease) increase in cash, cash equivalents and restricted cash

-40,605

-115,356

-97,650

105,436

50,312

159,425

211,694

2,552

-33,096

42,558

-40,509

-35,609

0

0

0

Noncash investing and financing activities:
Change in accounts payable and accrued liabilities related to property and equipment purchases

1,993

3,842

3,186

2,407

2,281

705

3,026

1,239

-408

-1,681

-1,982

927

0

0

0

Issuance of common stock warrant related to debt financing facility

-

-

-

-

-

-

-

83

83

83

83

0

0

0

0

Deferred financing costs for follow-on offering

-

-

21

-

-

-

115

0

0

0

0

-

-

-

-

Operating leases

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-